

Edgar Filing: COMPETITIVE TECHNOLOGIES INC - Form 8-K

COMPETITIVE TECHNOLOGIES INC
Form 8-K
December 16, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DECEMBER 16, 2008 (DECEMBER 12, 2008)
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)

COMPETITIVE TECHNOLOGIES, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE

(STATE OR OTHER JURISDICTION OF INCORPORATION)

1-8696

(COMMISSION FILE NUMBER)

36-2664428

(IRS EMPLOYER IDENTIFICATION NO.)

777 COMMERCE DRIVE, SUITE 100, FAIRFIELD, CONNECTICUT 06825

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)

(203) 368-6044

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:

N/A

(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01

On December 12, 2008, Competitive Technologies, Inc. (NYSE Alternext US: CTT) issued the following press release:

Edgar Filing: COMPETITIVE TECHNOLOGIES INC - Form 8-K

COMPETITIVE TECHNOLOGIES REPORTS FIRST QUARTER FISCAL 2009 RESULTS

FAIRFIELD, CT - (DECEMBER 12, 2008) - COMPETITIVE TECHNOLOGIES, INC. (NYSE ALTERNEXT US: CTT) today announced financial results for the first quarter fiscal 2009, ending October 31, 2008.

Expenses were substantially reduced for the fiscal first quarter ended October 31, 2008, decreasing 61% to approximately \$1.1 million, compared to approximately \$2.8 million in the prior year quarter. In September 2008, CTT recorded an expense reduction of \$0.4 million received from Federal Insurance Co. under its theft insurance policy relating to the Marcovitch, et al case.

"With several factors contributing to improving our financial picture, we believe we are moving in the right direction toward restoring profitability," said John B. Nano, CTT's Chairman, President and CEO. "We continue to reduce our costs and expect revenue to grow as we progress with our dynamic sales program for the pain management medical device and other products and technologies. In July 2008, we signed an equity financing arrangement with Fusion Capital for up to \$5.0 million of cash through sale of our common stock, at our option. Of the \$5.0 million, \$4.9 million remained available at October 31, 2008."

Total revenue for the fiscal first quarter ended October 31, 2008, was approximately \$0.1 million, compared to approximately \$0.2 million in the same period of the prior year.

"Sales and profit prospects for our pain management medical device are highly encouraging based on the European CE Mark approval for sale of the device," Mr. Nano continued. "We have signed four country-exclusive distribution agreements for the device including the countries of India, Korea, Bangladesh and Malaysia. We have responded fully to the US FDA to their request for information on our pending 510(k) application for sale of the device in the United States. We are continuing our review and selection process for distributors in Europe, Asia, the U.S. and other countries."

The net loss for the quarter is approximately \$1.0 million, or \$0.12 per share, a 62% improvement over the net loss of approximately \$2.6 million, or \$0.32 per share, for the prior year quarter.

Mr. Nano continued, "We have advised the NYSE Alternext that we will submit a plan by January 2, 2009 that will demonstrate our ability to achieve, within 18 months, compliance with the exchange listing standard below which we have fallen. We are in financial non-compliance as our shareholders' equity is less than \$4 million and we have had net losses in our three or our four most recent fiscal years. A "going concern" statement describing our declining financial condition, with our plans to halt this decline, was included with our Forms 10-Q, filed June 12, 2008, and 10-K and auditors report, filed October 28, 2008.

"As the pain management medical device attains mature market levels, we believe it will reach approximately \$200 million per year in distributor sales to hospitals and clinics. At that time, our revenue and profits from the device will dramatically exceed those produced by any other technology in CTT's 40-year history, resulting in approximately \$20 million per year to CTT, with limited related costs. CTT is aware of the needs expressed worldwide for treatment of pain, and is pleased to be part of the solution a

we aggressively market the device to meet those needs. There is exciting potential for the success of this device in the global pain management market; a market estimated to reach \$40 billion by 2010."

